Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/70757
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNarong Maneetonen_US
dc.contributor.authorBenchalak Maneetonen_US
dc.contributor.authorNuntaporn Karawekpanyawongen_US
dc.contributor.authorPakapan Woottiluken_US
dc.contributor.authorSuwannee Putthisrien_US
dc.contributor.authorManit Srisurapanonen_US
dc.date.accessioned2020-10-14T08:40:52Z-
dc.date.available2020-10-14T08:40:52Z-
dc.date.issued2020-10-01en_US
dc.identifier.issn15024725en_US
dc.identifier.issn08039488en_US
dc.identifier.other2-s2.0-85082852882en_US
dc.identifier.other10.1080/08039488.2020.1744037en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85082852882&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/70757-
dc.description.abstract© 2020 The Nordic Psychiatric Association. Background: Obsessive–compulsive disorder (OCD) is a common psychiatric illness in children and adolescents. Previous evidence suggests that fluoxetine is effective in the treatment of OCD in children and adolescents. However, those studies had small sample sizes. As a result, a systematic review, which is a more powerful method to calculate the true effect size, can be applied to examine the efficacy, acceptability and tolerability of fluoxetine in the treatment of OCD in children and adolescents. Objectives: The aims of this study were to review the efficacy, acceptability and tolerability of fluoxetine in the treatment of OCD in children and adolescents. Study appraisal and synthesis methods: The titles and abstracts collected from electronic databases were evaluated. Then, the full-text versions of relevant studies were thoroughly assessed and extracted. Results: A total of 188 randomized patients in three RCTs of fluoxetine versus placebo and one RCT of fluoxetine versus citalopram were included in this review. Considering efficacious outcomes, the pooled mean change score of the CY-BOCS in the fluoxetine-treated group was significantly greater than that in the placebo-treated group. Additionally, the CGI-S in the fluoxetine-treated group and the pooled mean change score of the NIMH-OC were also significantly different from those in the placebo-treated group. Limitation: This review included studies with small sample sizes. Conclusions and implications of key findings: Fluoxetine is associated with a significantly greater reduction in OCD severity, as measured by the CY-BOCS, NIMH-OC and CGI-S, in children and adolescents. Additionally, it is well tolerated in children and adolescents. The acceptability is comparable to that of the placebo-treated group. Nonetheless, further large prospective trials should be conducted to confirm these outcomes.en_US
dc.subjectMedicineen_US
dc.titleFluoxetine in acute treatment of children and adolescents with obsessive–compulsive disorder: a systematic review and meta-analysisen_US
dc.typeJournalen_US
article.title.sourcetitleNordic Journal of Psychiatryen_US
article.volume74en_US
article.stream.affiliationsFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.